Hematologic Oncology Update, Issue 1, 2016 (Video Program)ECHELON-1: A Phase III trial evaluating doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) versus brentuximab vedotin, doxorubicin, vinblastine and dacarbazine as front-line therapy for advanced classical HL
1:09 minutes.
TRANSCRIPTION:
DR LOVE: Where do things stand right now with your trial incorporating B vedotin up front? DR YOUNES: So the trial completed enrollment in the ECHELON-1, so we should learn about it — I think in 2 years from now we should have some interim analysis and know what’s going on. Knowing from the Phase I trial with the long-term follow-up that was updated about a year ago with 3-year follow-up, there’s about 92% progression-free survival, which is really remarkable. So I hope this randomized trial will be positive. And if it’s positive, it definitely will change the way we treat patients with Hodgkin lymphoma. DR LOVE: What do you think the tolerability is going to show, the 2 arms? DR YOUNES: From my experience in the Phase I, once the bleomycin was dropped, I mean, there was no major issue in tolerability. I mean, this is reasonably well tolerated. DR LOVE: Do you think it’ll be equally well tolerated or maybe better tolerated? DR YOUNES: Yes. It’s unlikely to be better tolerated, because we’re adding another drug, right? So there may be slightly more neuropathy, but there should be no major differences in tolerability. DR LOVE: How many patients are in the study? I would think in order to get the power, you would need quite a few. DR YOUNES: Yes, more than 1,000. |